Science Overview

Blood as a window to our health

We have been understanding our health through a number of blood tests in a large spectrum of scenarios; ranging from diabetes to heart attack, from pregnancy to cancer. We track proteins, circulating DNA, miRNA, etc

Advance technology

With the advancement of technology, we can now capture and digitize analytes in our blood quantitatively. Firefly is the technology we built with many years of efforts to accurately convert signals from circulating tumor DNA to infer tumor load of an individual.

Multi-analytes modeling

By gathering multi-omics information from a large population of healthy and cancer cohort, we train with the state-of-the-art machine learning algorithm to differentiate cancer and healthy status of an individual. 

Transforming cancer management

The potential applications of liquid biopsy are vast - from targeted cancer therapy selection to real-time minimal residual disease monitoring to population-level early screening - and we believe it will play a critical role in the future of cancer management. With more clinical studies that we're collecting, we will show clincal utility for different applications. For the next person coming to our clinic, we will take a snapshot with his blood and try to catch cancer in a stage that can be treated.

Shanghai Yunsheng Medical Laboratory joined the Inclusive Medical Association

May 14, 2018

Shanghai Yunsheng Medical Laboratory under AccuraGen Holdings participated in the launch of the Inclusive Medical Association.

Collaborator presented AccuraGen's ctDNA-NGS kit validation at AACR

April 25, 2018

The study was conducted by Professor Jiatao Lou, director of the Chest Hospital.

AccuraGen Clinical Laboratory obtained CAP accreditation

March 5, 2018

The High-throughput Sequencing (NGS) Laboratory of AccuraGen Holdings Group has been accredited by the College of American Pathologists (CAP).

AccuraGen passed the EQA of bioinformatics with full score

January 29, 2018

Shanghai Yunsheng Medical Laboratory Co., Ltd., a subsidiary of AccuraGen Holdings, passed the external quality evaluation with 100 marks.

AccuraGen was invited to PMWC to showcase the latest achievements in liquid biopsy

January 29, 2018

The Precision Medicine World Conference (PMWC) of 2018 was held in Silicon Valley from January 22 to 24 in the United States.